Group 1 - The core viewpoint highlights the ongoing challenges in the vaccine industry, including performance pressure, price wars, and policy disruptions, while acknowledging clear long-term growth drivers [3] - The recent report from the Shunde District Health Bureau indicates a total of 3,317 confirmed cases of Chikungunya fever, primarily in Lecong, Beijiao, and Chen Village, all classified as mild cases [2] - The World Health Organization warns that approximately 5.5 million people are at risk of Chikungunya fever, with transmission reported in 119 countries and regions [2] Group 2 - Short-term focus should be on the spread of diseases and the upcoming mid-year performance disclosures from related companies, monitoring price pressures and operational efficiency improvements [4] - The policy landscape is expected to adjust high-value drugs, including cancer vaccines and gene therapies, with potential for significant sales growth upon entering insurance coverage [4] - Long-term growth is driven by technological innovation in vaccine development, particularly in mRNA technology, which is expected to expand into respiratory viruses and cancer vaccines [5] Group 3 - The global market for vaccines is expanding, with significant opportunities in the "Belt and Road" countries, and the importance of WHO-PQ certification for domestic vaccine companies aiming for international markets [5] - The aging population and increased health awareness are driving demand for adult vaccines, with current penetration rates for vaccines like the flu vaccine and HPV vaccine being notably low in China [5] - The recent market rally is attributed to various factors, including event catalysts and funding dynamics, with a recommendation to monitor pandemic developments and policy progress [6]